CTOs on the Move

Repare Therapeutics

www.reparerx.com

 
Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare`s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Repare Therapeutics raised $68M on 06/22/2017

Similar Companies

Metagenomi

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

EMD Serono

EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany, employing over 1,200 individuals around the country with U.S. headquarters located in Rockland, Massachusetts. The company develops and offers therapies for specialty-care conditions, like multiple sclerosis, infertility and cancer. EMD Serono is committed to transforming lives by developing therapies that patients need and providing industry-leading educational and support programs.

Spaltudaq Corporation

Spaltudaq Corporation is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SenesTech

Left unchecked, two base rats, a male and a female, can result in 15,000 descendants in about 12 months. It`s easy to see how quickly this can lead to infestations and even population rebounds if just two rats are left behind after a knockdown program. That`s where we come in. We`re SenesTech, the rat fertility experts and the makers of ContraPest®, the first and only EPA-registered rat fertility restrictor impacting both male and female rats. We make it possible to target both ends of the lifecycle—birth and death—by adding fertility control to your integrated pest management (IPM) solution. Controlling the birth rate with ContraPest will magnify the success of your existing IPM protocols. ContraPest is the one-of-a-kind, innovative technology that targets the reproductive capabilities of both male and female Norway and roof rats. Sweet and fatty, it`s highly palatable like a “milkshake” rats can`t get enough of. By using ContraPest, you can reduce the rat population and keep it down because ContraPest works!

Casebia

Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.